Pharmaceutical composition comprising polypeptide
AssigneeD&D Pharmatech Inc.
InventorsKang Choon Lee, Og Yi Park, Hyoung Tae An, Eun Ji Park, Jae Hee Shin, Sung Mook Lim
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition including a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea, and has effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides.
Claims17
A polypeptide having an amino acid sequence represented by the following General Formula 1:
- [General Formula 1]
- (SEQ ID NOs. 8-9)
- R1-X1-QGTFTSDYSKYLD-R2-EFVQWLMNT-R3,
- wherein R1 is histidine, desamino-histidyl, N-dimethyl-histidyl, beta-hydroxy-imidazopropionyl, 4-imidazoacetyl, or beta-carboxy-imidazo-propionyl;
- X1 is a deletion, glycine, or aminoisobutyric acid (Aib);
- R2 is EQAAK (SEQ ID NO. 11), or EEAVK (SEQ ID NO. 12);
- and
- R3 is a deletion, cysteine, lysine, or methionine.
A method of preparing a pharmaceutical composition, the pharmaceutical composition comprising:
- a polypeptide having an amino acid sequence represented by the following Formula 1;
- and
- a non-peptidic polymer,
- the method comprising:
- mixing the non-peptidic polymer with the polypeptide to react with each other,
- wherein Formula 1 is
- (SEQ ID NOs:
- 8-9)
- R1-X1-QGTFTSDYSKYLD-R2-EFVQWLMNT-R3,
- wherein R1 is histidine, desamino-histidyl, N-dimethyl-histidyl, beta-hydroxy-imidazopropionyl, 4-imidazoacetyl, or beta-carboxy-imidazo-propionyl;
- X1 is a deletion, glycine, or aminoisobutyric acid (Aib);
- R2 is EQAAK (SEQ ID NO. 11), or EEAVK (SEQ ID NO. 12);
- and
- R3 is a deletion, cysteine, lysine, or methionine.
Dependencies are inferred from the claim text.